FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileApnimed, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
APMD
Apnimed, Inc. Stock AnalysisComprehensive stock analysis for Apnimed, Inc. (APMD) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAPMD
APMD
Apnimed, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
APMD
  1. Home
  2. Stocks
  3. Apnimed, Inc.
AP

Apnimed, Inc.

🇺🇸APMD•NASDAQ
AP

Apnimed, Inc.

🇺🇸APMD•NASDAQ
Market cap
$669.84M
P/E ratio
3.53

Your view on APMD

Mkt Cap
$669.84M
P/E
3.53
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Apnimed, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Kevin R. Lind
Headquarters
39 John F. Kennedy Street, Cambridge, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Kevin R. Lind
Headquarters
39 John F. Kennedy Street, Cambridge, MA, US
Description

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction.

The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Apnimed, Inc.. Starting points for Apnimed, Inc.: P/E 3.5, EPS $5.95, beta 7.95 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Apnimed, Inc.. Trailing twelve-month EPS for Apnimed, Inc. stands at $5.95. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
Analysts' target$60.00average of analysts' targets
Current price—

Targets, low to high

$60.00

Low $60.00

Middle $60.00

High $60.00

More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.84−$1.16$0.51−$3.44
Lowest estimate−$0.84−$1.43−$0.06−$5.55
Highest estimate−$0.84−$0.88$1.07−$1.33
Number of analysts1213
A year ago————
Growth vs a year ago————

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.00$0.00$99.37M$22.44M
Lowest estimate$0.00$0.00$82.41M$13.80M
Highest estimate$0.00$0.00$123.21M$32.25M
Number of analysts0024
A year ago————
Growth vs a year ago————
Recent rating and target changes (1)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Apnimed, Inc.. Apnimed, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold APMD14 companies · 8 funds
Compare APMD with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
INSPInspire Medical Systems, Inc.HealthcareMedical - Devices$1.6B
NYXHNyxoah S.A.HealthcareMedical - Specialties$82.0M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
VIRVir Biotechnology, Inc.HealthcareNASDAQ$1.4B
VIVSVivoSim Labs, Inc.HealthcareNASDAQ$4.3M
VKTXViking Therapeutics, Inc.HealthcareNASDAQ$3.2B
VNDAVanda Pharmaceuticals Inc.HealthcareNASDAQ$208.3M
VORVor Biopharma Inc.HealthcareNASDAQ$1.0B
VPROViropro Inc.HealthcareOTC$25,404
VRAXVirax Biolabs Group LimitedHealthcareNASDAQ$446,402
VRCAVerrica Pharmaceuticals Inc.HealthcareNASDAQ$47.1M
VRCIVerde Science, Inc.HealthcareOTC$239
VRDNViridian Therapeutics, Inc.HealthcareNASDAQ$3.4B
VRPXVirpax Pharmaceuticals, Inc.HealthcareNASDAQ$26,093
VRTXVertex Pharmaceuticals IncorporatedHealthcareNASDAQ$130.6B
ETFs holding Apnimed, Inc.
TickerFundFund assets% of the fund
IWMiShares Russell 2000 ETF$76.6B in assets0.01%
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VXFVanguard Extended Market ETF$30.2B in assets0.00%
VTWOVanguard Russell 2000 ETF$16.6B in assets0.01%
IBRNiShares Neuroscience and Healthcare ETF$9M in assets1.06%
RSSLGlobal X - Russell 2000 ETF$1.4B in assets0.01%
VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.01%
VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.01%

Largest holders first, then the funds most concentrated in APMD.

Open Comparable Analysis
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Apnimed, Inc. executives and directors. Shares of Apnimed, Inc. have traded between $16.12 and $29.15 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Apnimed, Inc.. Coverage tracks Apnimed, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Apnimed, Inc.

APMD AnalysisGood
Past
2
Growth
2
Health
4
Profit
5
Value
5